Impact of Clinical Pharmacist Diabetes Clinic on the Improvement of Health Outcomes in Type 2 Diabetes Subjects
DOI:
https://doi.org/10.3889/oamjms.2022.9518Keywords:
Clinical pharmacist, Diabetes clinic, Ambulatory care clinic, Collaborative outcomes, Multidisciplinary, Type 2 diabetes mellitusAbstract
AIM: This study aimed to evaluate the improvement of HbA1c, lipid profile, blood pressure readings, and weight in type 2 diabetes at the clinical pharmacist diabetes clinic (CPDC) in ambulatory care clinic.
METHODS: A retrospective study was conducted at a CPDC; the clinical pharmacist role was to follow-up the referred uncontrolled type 2 diabetes patients and providing comprehensive management.
RESULTS: A total of 419 patients were included the study. The mean ± standard error of the mean (SEM) age was 58.9 ± 0.59 years old. Sixty-two percent of the patients were female. At baseline, mean HbA1C ± SEM was 10.69% ± 0.06%, mean low-density lipoprotein (LDL) ± SEM was 2.66 ± 0.04 mmol/l. After 3 months of follow-up, HgbA1C had a statistically significant improvement by a reduction of 1.69% to be 9% ± 0.09% (95% confidence interval [CI] [1.50–1.87], p < 0.001). Moreover, mean HbA1C had a statistically significant improvement after 6 months of follow-up compared to baseline by 1.78% to be 8.9% ± 0.21% (95% CI [1.33–2.22], p < 0.001). LDL had a statistically significant improvement after 3 months by 0.24 mmol/l to be 2.42 ± 0.04 mmol/l (95% CI [0.15–0.35], p < 0.001) and after 6 months of follow-up by 0.28 mmol/l to be 2.38 ± 0.04 mmol/l (95% CI [0.20–0.36], p < 0.001).
CONCLUSION: The results stated that the clinical pharmacist anticipated care is achievable and had significant effect in the reduction of HbA1C and LDL levels in patients with uncontrolled type 2 diabetes.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021. p. 1-430.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843 PMid:31518657 DOI: https://doi.org/10.1016/j.diabres.2019.107843
Nazir MA, AlGhamdi L, AlKadi M, AlBeajan N, AlRashoudi L, AlHussan M. The burden of diabetes, its oral complications and their prevention and management. Open Access Maced J Med Sci. 2018;6(8):1545-53. https://doi.org/10.3889/oamjms.2018.294 PMid:30159091 DOI: https://doi.org/10.3889/oamjms.2018.294
ADA. Diabetes care. J Clin Appl Res Educ. 2022;45:1-270.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. https://doi.org/10.1056/NEJMoa012512 PMid:11832527 DOI: https://doi.org/10.1056/NEJMoa012512
Hippisley-Cox J, Coupland C. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: Open cohort study in primary care. BMJ. 2016;352:i1450. https://doi.org/10.1136/bmj.i1450 PMid:27029547 DOI: https://doi.org/10.1136/bmj.i1450
Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164(13):1422-6. https://doi.org/10.1001/archinte.164.13.1422 PMid:15249351 DOI: https://doi.org/10.1001/archinte.164.13.1422
ACCP. Standards of practice for clinical pharmacists. Pharmacotherapy. 2014;34(8):794-7. https://doi.org/10.1002/phar.1438 PMid: 25112523 DOI: https://doi.org/10.1002/phar.1438
Tadros L, Ledger-Scott M, Barnes E. The benefits of a pharmacist led type 2 diabetic clinic. Hosp Pharm. 2002;9:6-204.
Hughes JD, Wibowo Y, Sunderland B, Hoti K. The role of the pharmacist in the management of type 2 diabetes: current insights and future directions. Integr Pharm Res Pract. 2017;6:15-27. https://doi.org/10.2147/IPRP.S103783 PMid:29354547 DOI: https://doi.org/10.2147/IPRP.S103783
Alghadeer SM, Alsuwayni B, Almuwayjid AK, Almadi MS, Mubarak AM, Khunayn RM, et al. Glycemic Control and Management in Pharmacist-Led Diabetic Clinic vs. Physician- Led Diabetic Clinic. Medicina (Kaunas). 2021;58(1):14. https://doi.org/10.3390/medicina58010014 PMid:35056322 DOI: https://doi.org/10.3390/medicina58010014
Aguiar PM, da Silva CH, Chiann C, Dorea EL, Lyra DP Jr., Storpirtis S. Pharmacist-physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: Results from a randomized controlled trial. J Eval Clin Pract. 2018;24(1):22-30. https://doi.org/10.1111/jep.12606 PMid:27452158 DOI: https://doi.org/10.1111/jep.12606
Abdulrhim SH, Saleh RA, Hussain MA, Al Raey H, Babiker AH, Kheir N, et al. Impact of a collaborative pharmaceutical care service among patients with diabetes in an ambulatory care setting in Qatar: A multiple time series study. Value Health Reg Issues. 2019;19:45-50. https://doi.org/10.1016/j.vhri.2018.12.002 PMid:30875638 DOI: https://doi.org/10.1016/j.vhri.2018.12.002
Alsuwayni B, Alhossan A. Impact of clinical pharmacist-led diabetes management clinic on health outcomes at an academic hospital in Riyadh, Saudi Arabia: A prospective cohort study. Saudi Pharm J. 2020;28(12):1756-9. https://doi.org/10.1016/j.jsps.2020.11.002 PMid:33424266 DOI: https://doi.org/10.1016/j.jsps.2020.11.002
You L, Selvadurai S, Yee C, Noh N, Bao G, Joyce T, et al. Impact of pharmacist-managed Diabetes Medication Therapy Adherence Clinic (DMTAC) in government health clinics. Malays J Pharm Sci. 2015;13(1):43-51.
Shah RD, Braffett BH, Tryggestad JB, Hughan KS, Dhaliwal R, Nadeau KJ, et al. Cardiovascular risk factor progression in adolescents and young adults with youth-onset type 2 diabetes. J Diabetes Complications. 2022;36(3):108123. https://doi.org/10.1016/j.jdiacomp.2021.108123 PMid:35123868 DOI: https://doi.org/10.1016/j.jdiacomp.2021.108123
Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. J Manag Care Pharm. 2012;18(7):516-26. https://doi.org/10.18553/jmcp.2012.18.7.516 PMid:22971205 DOI: https://doi.org/10.18553/jmcp.2012.18.7.516
Javaid Z, Imtiaz U, Khalid I, Saeed H, Khan RQ, Islam M, et al. A randomized control trial of primary care-based management of type 2 diabetes by a pharmacist in Pakistan. BMC Health Serv Res. 2019;19(1):409. https://doi.org/10.1186/s12913-019-4274-z PMid:31234840 DOI: https://doi.org/10.1186/s12913-019-4274-z
Goruntla N, Mallela V, Nayakanti D. Impact of pharmacist-directed counseling and message reminder services on medication adherence and clinical outcomes in type 2 diabetes mellitus. J Pharm Bioallied Sci. 2019;11(1):69-76. https://doi.org/10.4103/jpbs.JPBS_211_18 PMid:30906142 DOI: https://doi.org/10.4103/JPBS.JPBS_211_18
Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): A randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193-206. https://doi.org/10.1016/S2213-8587(22)00008-0 PMid:35131037 DOI: https://doi.org/10.1016/S2213-8587(22)00008-0
Zhong P, Zeng H, Huang M, Fu W, Chen Z. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: A meta-analysis. Endocrine. 2022;75(3):718-24. https://doi.org/10.1007/s12020-021-02945-1 PMid:34981419 DOI: https://doi.org/10.1007/s12020-021-02945-1
Geerling R, Gray SM, Holmes-Truscott E, Speight J. ‘I need someone to believe in me and walk the journey with me’: A qualitative analysis of preferred approaches to weight management discussions in clinical care among adults with type 2 diabetes. Diabet Med. 2022;39(3):e14790. https://doi.org/10.1111/dme.14790 PMid:35030281 DOI: https://doi.org/10.1111/dme.14790
Pousinho S, Morgado M, Placido AI, Roque F, Falcao A, Alves G. Clinical pharmacists’ interventions in the management of type 2 diabetes mellitus: A systematic review. Pharm Pract (Granada). 2020;18(3):2000. https://doi.org/10.18549/PharmPract.2020.3.2000 PMid:32922572 DOI: https://doi.org/10.18549/PharmPract.2020.3.2000
Korcegez EI, Sancar M, Demirkan K. Effect of a Pharmacist- Led Program on Improving Outcomes in Patients with Type 2 Diabetes Mellitus from Northern Cyprus: A Randomized Controlled Trial. J Manag Care Spec Pharm. 2017;23(5):573-82. https://doi.org/10.18553/jmcp.2017.23.5.573 PMid:28448779 DOI: https://doi.org/10.18553/jmcp.2017.23.5.573
Mourao AO, Ferreira WR, Martins MA, Reis AM, Carrillo MR, Guimaraes AG, et al. Pharmaceutical care program for type 2 diabetes patients in Brazil: A randomised controlled trial. Int J Clin Pharm. 2013;35(1):79-86. https://doi.org/10.1007/s11096-012-9710-7 PMid:23161124 DOI: https://doi.org/10.1007/s11096-012-9710-7
Downloads
Published
How to Cite
License
Copyright (c) 2022 Nawal AlSubaie, Mohannad Alsallal, Sulaiman AlTwaijri, Ahmed AlOtaibi, Bandar AlHarbi, Mohammad AlEissa, Rana Alrashedi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
